Results 171 to 180 of about 12,634 (286)
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda +12 more
wiley +1 more source
Platform power, athlete branding, generative AI, and the future of sport governance-a systematic review. [PDF]
Westerbeek H, van Schaik T.
europepmc +1 more source
Harnessing the Power of Brand Attributes: The Impact on Corporate Brand Image and Customer Loyalty in Indonesian Islamic Banking [PDF]
Erdilia Adriasari +1 more
openalex +1 more source
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu +8 more
wiley +1 more source
Same brand, same flavour: but not the same product? [PDF]
Page MK +7 more
europepmc +1 more source
ABSTRACT Objective Cognitive impairment, fatigue, and depression are common in multiple sclerosis (MS), potentially due to disruption of regional functional connectivity caused by white matter (WM) lesions. We explored whether WM lesions functionally connected to specific brain regions contribute to these MS‐related manifestations.
Alessandro Franceschini +7 more
wiley +1 more source
Detecting freebooted content in social media ads: multimodal provenance and e-commerce implications. [PDF]
Weinlich P, Semeradova T.
europepmc +1 more source
Managing and Evaluating the Corporate Brand: A Model Suggestion Through the Case Analysis
Fabrizio Mosca +1 more
openalex +1 more source
The Contribution Of Corporate Social Responsibility On Brand Equity: The Case Of Bank Of Abyssinia
Helen A. Arega
openalex +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini +13 more
wiley +1 more source

